Clinical Trial Update: Study to Evaluate Efficacy and Safety of HH2853 in Relapsed/Refractory Peripheral T-cell Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial evaluating HH2853 for relapsed/refractory peripheral T-cell lymphoma is currently recruiting in Phase 1 and Phase 2.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Peripheral T-cell Lymphoma

Drugs mentioned

• HH2853

Snippet

Sponsor: Haihe Biopharma Co., Ltd. | Conditions: Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL) | Phase 1, Phase 2 | Status: RECRUITING